Co-PSMA trial: Recruitment successfully completed
- Written by PR Newswire Asia - Asian Spectator
![]() |
SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) led...






